BiotechTV

•

Channel • 5 Shows

Life Sciences

Life Sciences

Updated Biweekly
Life Sciences

Life Sciences

Updated 2d ago
Life Sciences

Life Sciences

Updated Jun 25
Life Sciences

Life Sciences

Updated Mar 5
Life Sciences

Life Sciences

Updated Jul 23

Jul 27

Episode 44: BainCapital's Adam Koppel

Adam Koppel describes his career path, which included a stop at McKinsey, Biogen, and twice at Bain (where he is now). He descrbies the private equity model they have been on the leading edge of, and his take on where we are in the biotech cycle. Plus, the critical importance of mentors.
2d ago

LifeMine Therapeutics announced a $263M raise today to help accelerate the development of its novel calcineurin activation inhibitor that aims to radically change the profile of organ transplants

Co-Founder, President & CEO Greg Verdine describes the toxicity issues associated with the immuosupressive drugs that transplant recipients currently receive, and explains how LIFE-001 is different. Plus, given how the therapy is designed to safely prevent T-cell activation and proliferation, there could also ultimately be an autoimmune use case as well.
Jul 13

Episode 43: Lightstone Venture's Mike Carusi

Mike Carusi describes his early life and career, how gaining an appreciation for sales made an impression on him early on, and his philosophy of investing in medical devices - and the similarities and differences between that and investing in therapeutics.
Jun 25

Episode 7: Perceptive Advisors' Joe Edelman discusses how biotech investing has changed over his extensive career, and his thoughts on running an investment firm

He describes to Matt how the market has become more efficient since he started in the 1990's. He shares his perspective on single-asset vs pipeline companies, and today's M&A dynamic. Plus, his goal of being unbiased as an investor and how he tries to create an environment at Perceptive where that style is instilled in his analysts.
Jul 27

U.S. Science Summit: Biotech veteran Harvey Berger presents an overview of the history of Kendall Square and what is at stake to keep it a leader in life sciences

Dr. Berger, who founded Ariad Pharmaceuticals here in 1991, describes Kendall's transition from candy factories, to Polaroid, to what it is today.
Jul 23

U.S. Science Summit: "Who will shape the future of Bio?" with Recursion President & CEO Najat Khan

Interviewed by HSBC Innovation Banking's Katherine Andersen, Najat Khan discusses AI, her priorities upon taking the role of CEO at Recursion earlier this year, encouraging employees to speak more than just one language of expertise, and women in leadership.
Jun 1

Episode 41: Forbion's Nanna Lüneborg

Nanna Luneborg discusses hear career and joining Forbion. She describes the firm's investment approach, and her experience with everything from seed, to private, and to public investing in life sciences. Plus, thoughts on China and AI in biotech.
Jun 15

Episode 42: Nextech's Thilo Schroeder

Having been an early investor in many recent successes such as Revolution Medicines, Peloton, and Parabilis Medicines, he describes his investment philosophy and focus on precision oncology companies. Plus, his early life, getting hands on experience in biotech at Micromet, and learning from some of the top investors and scientific advisors in the industry.
May 18

Episode 40: GV's Krishna Yeshwant

He describes his well-rounded background of studying and working in both software in Silicon Valley and Medicine in Boston, and the start of GV. He describes a conservative start to investing at GV, but also today how Alphabet's scale and cash gives them the ability to ride cycles and make concentrated bets on companies the team has conviction on.
Jul 27

U.S. Science Summit: Curie.Bio Chairman Alexis Borisy and Parabilis Medicines CEO Mathai Mammen discusses the funding environment for biotech and communicating their work to the public

Alexis Borisy recounts the story of Revolution Medicines, which delivered the pancreatic cancer breakthrough this year, and talks about the health of the founder led side of the biotech sector. Mathai Mammen recently took Parabilis public in the largest IPO in biotech history, and describes the science that made it possible.

BiotechTV covers the biotechnology sector through news, stories, podcasts, and educational videos.

Website

BiotechTV

Top Shows

Episode 44: BainCapital's Adam Koppel

LifeMine Therapeutics announced a $263M raise today to help accelerate the development of its novel calcineurin activation inhibitor that aims to radically change the profile of organ transplants

Episode 43: Lightstone Venture's Mike Carusi

Episode 7: Perceptive Advisors' Joe Edelman discusses how biotech investing has changed over his extensive career, and his thoughts on running an investment firm

U.S. Science Summit: Biotech veteran Harvey Berger presents an overview of the history of Kendall Square and what is at stake to keep it a leader in life sciences

U.S. Science Summit: "Who will shape the future of Bio?" with Recursion President & CEO Najat Khan

Episode 41: Forbion's Nanna Lüneborg

Episode 42: Nextech's Thilo Schroeder

Episode 40: GV's Krishna Yeshwant

U.S. Science Summit: Curie.Bio Chairman Alexis Borisy and Parabilis Medicines CEO Mathai Mammen discusses the funding environment for biotech and communicating their work to the public

About

BiotechTV

Top Shows

Top Episodes

About